Genitourinary infections in diabetic patients in the new era of diabetes therapy with sodium-glucose cotransporter-2 inhibitors

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 26, Issue 11, 2016, Pages 963-970

  Rizzi, M ^a   Trevisan, R ^b  

^a Antiviral Therapy Unit   (Italy)

^b Division of Endocrinology   (Italy)

Author keywords

Asymptomatic bacteriuria; Diabetes; Genital infection; Glycosuria; Sodium glucose cotransporter 2 inhibitors; Urinary tract infection

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLIMEPIRIDE; GLIPIZIDE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ASYMPTOMATIC BACTERIURIA; DIABETES MELLITUS; FUNGAL COLONIZATION; GENITAL TRACT INFECTION; GLUCOSURIA; GLYCEMIC CONTROL; HUMAN; KIDNEY FUNCTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; URINARY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; GENITAL DISEASES, FEMALE; GENITAL DISEASES, MALE; GLUCOSE BLOOD LEVEL; INCIDENCE; KIDNEY; MALE; METABOLISM; MICROBIOLOGY; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; URINARY TRACT INFECTIONS;

BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS; FEMALE; GENITAL DISEASES, FEMALE; GENITAL DISEASES, MALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; KIDNEY; MALE; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; URINARY TRACT INFECTIONS;

EID: 84992533004     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2016.07.006     Document Type: Review

References (71)

1. [1] Korbel, L., Spencer, J.D., Diabetes mellitus and infections: an evaluation of hospital utilization and management costs in the Unites States. J Diabetes Complicat 29 (2015), 192–195.
2. [2] Moss, S.E., Klein, R., Klein, B.E., Cause-specific mortality in a population-based study of diabetes. Am J Public Health 81 (1991), 1158–1162.
3. [3] Gu, K., Cowie, C.C., Harris, M.I., Mortality in adults with and without diabetes in a national cohort of the US population, 1971–1993. Diabetes Care 21 (1998), 1138–1145.
4. [4] Bertoni, A.G., Saydah, S., Brancati, F.L., Diabetes and the risk of infection-related mortality in the U.S. Diabetes Care 24 (2001), 1044–1049.
5. [5] Peleg, A.Y., Weerarathna, T., McCarthy, J.S., Davis, T.M., Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev 23 (2007), 3–13.
6. [6] Joshi, N., Caputo, G.M., Weitekamp, M.R., Karchmer, A.W., Infections in patients with diabetes mellitus. N Engl J Med 341 (1999), 1906–1912.
7. [7] Shah, B.R., Hux, J.E., Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 26 (2003), 510–513.
8. [8] Muller, L.M., Gorter, K.J., Hak, E., Goudzwaard, W.L., Schellevis, F.G., Hoepelman, A.I., et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 41 (2005), 281–288.
9. [9] Rammaert, B., Lanternier, F., Poirée, S., Kania, R., Lortholary, O., Diabetes and mucormycosis: a complex interplay. Diabetes Metab 38:3 (2012 Jun), 193–204, 10.1016/j.diabet.2012.01.002 Review.
10. [10] Hostetter, M.K., Handicaps to host defense. Effects of hyperglycemia on C3 and Candida albicans. Diabetes 39 (1990), 271–275.
11. [11] Latham, R., Lancaster, A.D., Covington, J.F., Pirolo, J.S., Thomas, C.S. Jr., The association of diabetes and glucose control with surgical-site infections among cardiothoracic surgery patients. Infect Control Hosp Epidemiol 22 (2001), 607–612.
12. [12] Guvener, M., Pasaoglu, I., Demircin, M., Oc, M., Perioperative hyperglycemia is a strong correlate of postoperative infection in type II diabetic patients after coronary artery bypass grafting. Endocr J 49 (2002), 531–537.
13. [13] Marchant, M.H. Jr., Viens, N.A., Cook, C., Vail, T.P., Bolognesi, M.P., The impact of glycemic control and diabetes mellitus on perioperative outcomes after total joint arthroplasty. J Bone Jt Surg Am 91 (2009), 1621–1629.
14. [14] Yo, C.H., Lee, M.T., Gi, W.T., Chang, S.S., Tsai, K.C., Chen, S.C., et al. Prognostic determinants of community-acquired bloodstream infection in type 2 diabetic patients in ED. Am J Emerg Med 32 (2014), 1450–1454.
15. [15] Pearson-Stuttard, J., Blundell, S., Harris, T., Cook, D.G., Critchley, J., Diabetes and infection: assessing the association with glycaemic control in population-based studies. Lancet Diabetes Endocrinol 4 (2016), 148–158.
16. [16] Willemen, M.J., Mantel-Teeuwisse, A.K., Straus, S.M., Meyboom, R.H., Egberts, T.C., Leufkens, H.G., Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care 34 (2011), 369–374.
17. [17] Williams-Herman, D., Engel, S.S., Round, E., Johnson, J., Golm, G.T., Guo, H., et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord, 10, 2010 Apr 22, 7.
18. [18] Schernthaner, G., Barnett, A.H., Emser, A., Patel, S., Troost, J., Woerle, H.J., et al. Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus. Diabetes Obes Metab 14 (2012), 470–478.
19. [19] Goßen, K., Gräber, S., Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes, Obes Metab 14 (2012), 1061–1072.
20. [20] Montilla, S., Marchesini, G., Sammarco, A., Trotta, M.P., Siviero, P.D., Tomino, C., et al., AIFA Anti-diabetics Monitoring Group. Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry. Nutr Metab Cardiovasc Dis 24 (2014), 1346–1353.
21. [21] Tricco, A.C., Antony, J., Khan, P.A., Ghassemi, M., Hamid, J.S., Ashoor, H., et al. Safety and effectiveness of dipeptyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis. BMJ Open, 4(12), 2014 Dec 23, e005752, 10.1136/bmjopen-2014-005752.
22. [22] Zhanel, G.G., Nicolle, L.E., Harding, G.K., Prevalence of asymptomatic bacteriuria and associated host factors in women with diabetes mellitus. The Manitoba Diabetic Urinary Infection Study Group Clin Infect Dis 21 (1995), 316–322.
23. [23] Geerlings, S.E., Stolk, R.P., Camps, M.J.L., Netten, P.M., Collet, J.T., Hoepelman, A.I.M., on behalf of the Diabetes Mellitus Asymptomatic Bacteriuria Utrecht Study Group. Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care 23 (2000), 1737–1741.
24. [24] Bonadio, M., Boldrini, E., Forotti, G., Matteucci, E., Vigna, A., Mori, S., et al. Asymptomatic bacteriuria in women with diabetes: influence of metabolic control. Clin Infect Dis 38 (2004), e41–e45.
25. [25] Boyko, E.J., Fihn, S.D., Scholes, D., Abraham, L., Monsey, B., Risk of urinary tract infection and asymptomatic bacteriuria among diabetic and nondiabetic postmenopausal women. Am J Epidemiol 161 (2005), 557–564.
26. [26] Ishay, A., Lavi, I., Luboshitzky, R., Prevalence and risk factors for asymptomatic bacteriuria in women with type 2 diabetes mellitus. Diabet Med 23 (2006), 185–188.
27. [27] Renko, M., Tapanainen, P., Tossavainen, P., Pokka, T., Uhari, M., Meta-analysis of the significance of asymptomatic bacteriuria in diabetes. Diabetes Care 34 (2011), 230–235.
28. [28] Meiland, R., Geerlings, S.E., Stolk, R.P., Netten, P.M., Schneeberger, P.M., Hoepelman, A.I., Asymptomatic bacteriuria in women with diabetes mellitus: effect on renal function after 6 years of follow-up. Arch Intern Med 166 (2006), 2222–2227.
29. [29] Harding, G.K., Zhanel, G.G., Nicolle, L.E., Cheang, M., Manitoba Diabetes Urinary Tract Infection Study Group. Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. N Engl J Med 347 (2002), 1576–1583.
30. [30] Dalal, S., Nicolle, L., Marrs, C.F., Zhang, L., Harding, G., Foxman, B., Long-term Escherichia coli asymptomatic bacteriuria among women with diabetes mellitus. Clin Infect Dis 49 (2009), 491–497.
31. [31] Zalmanovici, T.A., Lador, A., Sauerbrun-Cutler, M.T., Leiboici, L., Antibiotics for asymptomatic bacteriuria (review). Cochrane Database Syst Rev, 4, 2015 Apr 8 CD009534. [Epub ahead of print].
32. [32] Janifer, J., Geethalakshmi, S., Satyavani, K., Viswanathan, V., Prevalence of lower urinary tract infection in South Indian type 2 diabetic subjects. Indian J Nephrol, 20, 2010, 120.
33. [33] Hirji, I., Guo, Z., Andersson, S.W., Hammar, N., Gomez-Caminero, A., Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD). J Diabetes Complicat 26 (2012), 513–516.
34. [34] Yu, S., Fu, A.Z., Qiu, Y., Engel, S.S., Shankar, R., Brodovicz, K.G., et al. Disease burden of urinary tract infections among type 2 diabetes mellitus patients in the U.S. J Diabetes Complicat 28 (2014), 621–626.
35. [35] Nicolle, L.E., Bradley, S., Colgan, R., Rice, J.C., Schaeffer, A., Hooton, T.M., Infectious Diseases Society of America; American Society of Nephrology; American Geriatric Society. Infectious diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 40 (2005), 643–654.
36. [36] Aswani, S.M., Chandrashekar, U., Shivashankara, K., Pruthvi, B., Clinical profile of urinary tract infecions in diabetics and non-diabetics. Australas Med J 7:1 (2014), 29–34.
37. [37] Carton, J.A., Maradona, J.A., Nuño, F.J., Fernandez-Alvarez, R., Pérez Gonzalez, F., Asensi, V., Diabetes mellitus and bactaeremia: a comparative study between diabetic and non-diabetic patients. Eur J Med 5 (1992), 281–287.
38. [38] Sanden, A.K., Johansen, M.B., Pedersen, L., Lervang, H.H., Schønheyder, H.C., Thomsen, R.W., Change from oral antidiabetic therapy to insulin and risk of urinary tract infections in type 2 diabetic patients: a population-based prescription study. J Diabetes Complicat 24 (2010), 375–381.
39. [39] Geerlings, S.E., Stolk, R.P., Camps, M.J.L., Netten, P.M., Hoekstka, J.B.L., Bouter, K.P., et al., for the Diabetes Mellitus Asymptomatic Bacteriuria Utrecht Study Group. Asymptomatic bacteriuria may be considered a complication in women with diabetes. Diabetes Care 23 (2000), 744–749.
40. [40] Santer, R., Kinner, M., Lassen, C.L., Schneppenheim, R., Eggert, P., Bald, M., et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 14 (2003), 2873–2882.
41. [41] Hooton, T.M., Scholes, D., Hughes, J.P., Winter, C., Roberts, P.L., Stapleton, A.E., et al. A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med 335 (1996), 468–474.
42. [42] Scholes, D., Hooton, T.M., Roberts, P.L., Stapleton, A.E., Gupta, K., Stamm, W.E., Risk factors for recurrent urinary tract infection in young women. J Infect Dis 182 (2000), 1177–1182.
43. [43] Geerlings, S.E., Brouwer, E.C., Gaastra, W., Stolk, R.P., Hoepelman, A.I.M., Virulence factors of Escherichia coli isolated from urine of diabetic women with asymptomatic bacteriuria: correlation with clinical characteristics. Ant Van Leeuwenhoek 80 (2001), 119–127.
44. [44] Meiland, R., Geerlings, S.E., De Neeling, A.J., Hoepelman, A.I., Diabetes mellitus in itself is not a risk factor for antibiotic resistance in Escherichia coli isolated from patients with bacteriuria. Diabet Med 21 (2004), 1032–1034.
45. [45] Nyirjesy, P., Sobel, J.D., Genital mycotic infections in patients with diabetes. Postgrad Med 125 (2013), 33–46.
46. [46] Donders, G.G.G., Prenen, H., Verbeke, G., Reybrouck, R., Impaired tolerance for glucose in women with recurrent vaginal candidiasis. Am J Obstet Gynecol 187 (2002), 989–993.
47. [47] Goswami, R., Dadhwal, V., Tejaswi, S., Datta, K., Paul, A., Haricharan, R.N., et al. Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status. J Infect 41 (2000), 162–166.
48. [48] De Leon, E.M., Jacober, S.J., Sobel, J.D., Foxman, B., Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes. BMC Infect Dis, 2, 2002, 1.
49. [49] Fakjian, N., Hunter, S., Cole, G.W., Miller, J., An argument for circumcision. Arhc Dermatol 126 (1990), 1046–1047.
50. [50] Anderson, M.R., Klink, K., Cohrssen, A., Evaluation of vaginal complaints. JAMA 291 (2004), 1368–1379.
51. [51] Sobel, J.D., Vulvovaginal candidosis. Lancet 369:9577 (2007), 1961–1971.
52. [52] Tang, L.M., Su, Y.J., Lai, Y.C., The evaluation of microbiology and prognosis of Fournier's gangrene in past five years. Springerplus, 4, 2015 Jan 13, 14, 10.1186/s40064-014-0783-8 eCollection 2015.
53. [53] Geerlings, S.E., Fonseca, V., Castro-Diaz, D., List, J., Parikh, S., Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract 103 (2014), 373–381.
54. [54] Mearns, E.S., Sobieraj, D.M., White, C.M., Saulsberry, W.J., Kohn, C.G., Doleh, Y., et al. Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis. PLoS One, 10, 2015, e0125879.
55. [55] Whalen, K., Miller, S., Onge, E.S., The role of sodium-glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes. Clin Ther 37 (2015), 1150–1166.
56. [56] Johnsson, K.M., Ptaszynska, A., Schmitz, B., Sugg, J., Parikh, S.J., List, J.F., Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complicat 27 (2013), 473–478.
57. [57] Johnsson, K.M., Ptaszynska, A., Schmitz, B., Sugg, J., Parikh, S.J., List, J.F., Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complicat 27 (2013), 479–484.
58. [58] Del Prato, S., Nauck, M., Durán-Garcia, S., Maffei, L., Rohwedder, K., Theuerkauf, A., et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab 17 (2015), 581–590.
59. [59] Cefalu, W.T., Leiter, L.A., de Bruin, T.W., Gause-Nilsson, I., Sugg, J., Parikh, S.J., Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care 38 (2015), 1218–1227.
60. [60] Matthaei, S., Bowering, K., Rohwedder, K., Grohl, A., Parikh, S., Study 05 Group. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care 38 (2015), 365–372.
61. [61] Strojek, K., Yoon, K.H., Hruba, V., Sugg, J., Langkilde, A.M., Parikh, S., Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial. Diabetes Ther 5 (2014), 267–283.
62. [62] Neumiller, J.J., Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Drugs Context, 3, 2014, 212262.
63. [63] Kovacs, C.S., Seshiah, V., Swallow, R., Jones, R., Rattunde, H., Woerle, H.J., et al., EMPA-REG PIO™ trial investigators. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 16 (2014), 147–158.
64. [64] Häring, H.U., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Woerle, H.J., et al., EMPA-REG METSU Trial Investigators. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 36 (2013), 3396–3404.
65. [65] Häring, H.U., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Woerle, H.J., et al., EMPA-REG METSU Trial Investigators. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 37 (2014), 1650–1659.
66. [66] Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al., EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
67. [67] Nyirjesy, P., Zhao, Y., Ways, K., Usiskin, K., Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 28 (2012), 1173–1178.
68. [68] Usiskin, K., Kline, I., Fung, A., Mayer, C., Meininger, G., Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results. Postgrad Med 126 (2014), 16–34.
69. [69] Bode, B., Stenlof, K., Harris, S., Sullivan, D., Fung, A., Usiskin, K., et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab 17 (2015), 294–303.
70. [70] Leiter, L.A., Yoon, K.H., Arias, P., Langslet, G., Xie, J., Balis, D.A., et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care 38 (2015), 355–364.
71. [71] Lavalle-González, F.J., Januszewicz, A., Davidson, J., Tong, C., Qiu, R., Canovatchel, W., et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 56 (2013), 2582–2592.